Drugs / JNJ-80948543
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06660563 | Oct 2024 → Jan 2026 overdue | non-Hodgkin lymphoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06139406 | Dec 2023 → Jan 2026 overdue | non-Hodgkin lymphoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05424822 | Aug 2022 → Oct 2025 overdue | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-80948543 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06139406 ↗ |
| Route | Intravenous | “JNJ-80948543 will be administered as SC or IV injection.” NCT05424822 ↗ |
| Route | Subcutaneous | “JNJ-80948543 will be administered as SC or IV injection.” NCT05424822 ↗ |
| Target | CD79B | “T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody” NCT05424822 ↗ |